| Identification | Back Directory | [Name]
Vodobatinib | [CAS]
1388803-90-4 | [Synonyms]
Vodobatinib
2-Chloro-6-methyl-N'-(4-methyl-3-(quinolin-3-ylethynyl)benzoyl)benzohydrazide
N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide
Benzoic acid, 2-chloro-6-methyl-, 2-[4-methyl-3-[2-(3-quinolinyl)ethynyl]benzoyl]hydrazide | [Molecular Formula]
C27H20ClN3O2 | [MDL Number]
MFCD34167514 | [MOL File]
1388803-90-4.mol | [Molecular Weight]
453.92 |
| Chemical Properties | Back Directory | [Boiling point ]
748.6±60.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (275.38 mM; Need ultrasonic) | [form ]
Solid | [pka]
10.09±0.23(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research[1][2]. Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [IC 50]
BCR-ABL1: 7 nM (IC50) | [References]
[1] Orlando Antelope, et al. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol. 2019 Sep;77:36-40.e2. DOI:10.1016/j.exphem.2019.08.007
[2] Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Session: 632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond. |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|